The register-based incidence estimates of RA and PsA in Norway are slightly higher than in previous Norwegian studies, and it was found that risk of RA and PsA was higher among persons with lower education level. Even in the 2010s, Norwegian RA patients suffer from excess mortality compared to the general population. In contrast, mortality among PsA patients was similar to the general population, which may relate to an overall milder disease course and/or improved treatment. In addition to effective suppression of disease activity, our findings warrant further attention to comorbidity prevention in RA.
Among Finnish RA patients, long-term outcomes after myocardial infarction (MI) compared to the general population are impaired. Glucocorticoid use before MI is associated with higher mortality and recurrent MI. Secondary prevention of CVD among RA patients should be prioritized.